

Variation in the Incidence of ventriculostomy related infection in critically ill patients

Variation in the incidence of ventriculostomy related infection

Sara N. Bassin,^{1,2} David H. Tian MD,^{1,3} Simon Chadwick,^{1,4} Sajeer Mahendran,¹ Oliver Flower,^{1,4} Emily Fitzgerald,^{1,4} Jonathon Parkinson,^{5,6} Archie Darbar,⁷ Pierre Janin,¹ Anthony Delaney*^{1,4,7}

1. Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, New South Wales. Australia.
2. Department of Intensive Care, St Vincent's Hospital, New South Wales. Australia.
3. Department of Anaesthesia, Westmead Hospital, New South Wales. Australia.
4. Northern Clinical School, Sydney Medical School, University of Sydney, New South Wales, Australia
5. Department of Neurosurgery, Royal North Shore Hospital, New South Wales, Australia
6. Surgical Education, Research and Training Unit, University of Sydney, New South Wales, Australia
7. Department of Microbiology and Infectious Diseases, Royal North Shore Hospital, New South Wales, Australia
8. Division of Critical Care, The George Institute for Global Health, New South Wales, Australia

Corresponding author

A/Prof Anthony Delaney,

Senior Staff Specialist, Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital

Reserve Rd, St. Leonards, NSW, 2065, Australia

Email: anthony.delaney@sydney.edu.au

ORCID:

Anthony Delaney: 0000-0002-1015-7146

Keywords: Ventriculostomy related infection, ventriculitis, external ventricular drain, surgical infections

Abstract

Introduction

Ventriculostomy related infection (VRI) or ventriculitis is a common and serious complication related to the placement of an external ventricular drain. Numerous sets of diagnostic criteria for VRI have been reported. We sought to estimate the variation in the incidence of VRI in a cohort of patients according to published diagnostic criteria.

Materials and Methods

We conducted a retrospective cohort study. We included adult patients admitted to the Neuroscience intensive care unit with traumatic brain injury (TBI), subarachnoid haemorrhage (SAH) and intracerebral haemorrhage (ICH) who required an EVD. We estimated the incidence of VRI according to published diagnostic criteria. We compared the incidence to clinicians' diagnoses of VRI. The primary outcome was the estimated incidence of VRI.

Results

There were 190 study participants, median age (interquartile range) of 58 (48 - 72), 106 (55.8%) were female. Admitting diagnoses was ICH in 30 (15.8%), TBI in 49 (25.8%) and SAH in 111 (58.4%) of cases respectively. There were 158 (83.2%) who required mechanical ventilation for a median of 6 (2-13) days. There were 29 (15.3%) who were treated for VRI by clinicians, with 6 (3.2%) having a positive culture. Variation in the diagnostic criteria led to an estimated incidence of VRI that ranged from 1 (0.5%) to 178 (93.7%).

Conclusion

In this critically ill cohort, the estimated incidence of VRI varied widely depending on which diagnostic criteria for VRI were applied. A comprehensive, consistent, objective and universal set of diagnostic criteria for ventriculostomy related infection is needed.

Introduction

The insertion of an external ventricular drain (EVD) is one of the most common neurosurgical procedures, generally undertaken for the treatment of acute hydrocephalus or for monitoring intracranial pressure.¹ While the insertion of an EVD may be life-saving, the procedure has known complications including infection, haemorrhage and misplacement of the catheter.² Infection, referred to as ventriculostomy related infection (VRI) is the most common and clinically significant complication of EVD placement.³ Patients with VRI appear to have an increased risk of morbidity,⁴ mortality,⁵ increased Intensive Care Unit (ICU) and hospital length of stay, with increased cost of care.⁶

Strategies to ameliorate the adverse consequences of VRI are required and guidelines for the management of EVDs have been produced.⁷ A key difficulty in providing robust evidence based-recommendations for the prevention of VRI is that there is no consistent set of diagnostic criteria for VRI.⁷ A systematic review in 2016 reported identifying 17 separate published definitions of VRI, with an estimate of the incidence of VRI in a test cohort that ranged from 22% to 94%.⁸ An underreported issue confronting clinicians attempting to diagnose VRI in a critically ill population is that many definitions of VRI require clinical parameters such as the presence of headache, neck stiffness or altered level of consciousness that are unreliable due to the confounding effects of the primary condition that necessitated the insertion of the EVD (e.g., subarachnoid haemorrhage) or by the treatments provided to patients with acute severe brain injury, such as tracheal intubation and the provision of intravenous sedative and analgesic agents.^{9,10}

The lack of clarity in the diagnostic criteria for VRI creates problems for clinicians. While underdiagnosis may lead to missed opportunities to intervene and reduce preventable morbidity and mortality,¹¹ over treatment is associated with potential adverse events.¹² It is not clear how the various diagnostic criteria for VRI are implemented in routine clinical practice. Therefore, we conducted a retrospective observational study to assess the variation between the incidence of VRI diagnosed and treated in the clinical setting and the estimated incidence of VRI using the published diagnostic criteria.⁸

Materials and methods

Study design and setting:

This retrospective cohort study was conducted in the Neuroscience Intensive Care Unit at the Royal North Shore Hospital. The Royal North Shore Hospital is a 600-bed referral centre in Sydney, Australia. The Neuroscience Intensive Care Unit is a dedicated 13 bed Neurocritical care unit that admits approximately 800 patients per year. Clinical and laboratory data from patients with traumatic brain injury (TBI), subarachnoid haemorrhage (SAH) and intracerebral haemorrhage (ICH) admitted to the Neuroscience ICU are collected in a prospective registry, the Neurological Outcomes in Intensive Care (NOICE) registry, which was used for the conduct of this study.¹³ Data regarding CSF microbiology and biochemistry were extracted separately. Ethics approval to conduct the study was obtained from the Northern Sydney Local Health District Human Research Ethics Committee (RESP/18/339). The report was structured according to the guidelines suggested by the STROBE statement.¹⁴

Participants:

We included data from adult patients admitted to the Neuroscience ICU from January 1st 2015 to July 22nd 2018 with a TBI, SAH or ICH, who had an EVD placed for a clinical indication and had at least one CSF specimen collected.

Data Sources and Variables:

Data collected from the NOICE registry included patient demographics and comorbidities, dates of hospital, ICU admission and discharge, primary neurosurgical pathology, illness severity scoring, clinical and laboratory data on admission and daily measures, treatment modalities, and complications of ICU stay. We also collected data to grade the severity of illness for each condition. For patients with SAH, three scoring systems were used; The World Federation of Neurosurgical Societies clinical grading system,¹⁵ and the Fisher and Claassen radiological grading systems.¹⁶ For patients with TBI, the Marshall CT classification system was used.¹⁷ In the patients who had an ICH, the ICH score was used.¹⁸ We collected data regarding the haematological and biochemical profile of any CSF specimens as well as the results of microscopy and culture results.

A confirmed clinical diagnosis of VRI was recorded in our cohort for patients when there was growth of a pathogenic organism in the CSF cultures. A treated clinical case of VRI was recorded when a patient was recorded as receiving intravenous antibiotics due to clinical

diagnosis of VRI. A suspected case of VRI was recorded when the CSF white cell count: red cell count ratio was $>1:200$.

The estimated incidence of VRI according to our clinical criteria was compared to the estimated incidence of VRI obtained by using the various criteria set out in the published literature.⁸ The full details of the 17 sets of diagnostic criteria for ventriculitis can be found in Appendix 1. From each set of diagnostic criteria, we used the published thresholds for CSF parameters including white cell count (WCC), red cell count (RCC) to WCC ratio, CSF protein and glucose concentration, physiological variables (including temperature), and laboratory values such as peripheral WCC. When parameter cut-offs were not specified we used the abnormal CSF and laboratory parameters outlined in the Royal College of Pathologists of Australasia manual (CSF cell count $< 5 \times 10^6/L$ mononuclears; no neutrophils or red cells, glucose 2.8-4.4mmol/L, protein 0.15-0.45g/L, WCC (polymorph) to RCC ratio $> 1:200$, peripheral WCC $> 11 \times 10^9/L$).¹⁹ If the definition did not specify a cut-off for fever, we used a temperature $> 38^\circ C$. Details regarding timing of EVD insertion and removal in relation to the timing of CSF sampling were applied when definitions specified these criteria. Variables that were subjective, such as headache, altered mental status, photophobia, nuchal rigidity and other clinical signs of meningitis that were not reliably obtainable in a critically ill population of patients due to mechanical ventilation, sedation or underlying disease process were excluded from 9 sets²⁰⁻²⁸ of diagnostic criteria. There were 3 sets of diagnostic criteria that contained data that are not routinely available,^{23, 29, 30} the number of colony forming units/0.1 ml of CSF, the type of media the organism was grown on and antibody titres. The modified diagnostic criteria for VRI are shown in Supplementary Table 2.

Statistical methods:

Demographic data and clinical outcomes are presented as mean \pm standard deviation for normally distributed continuous data, or median (interquartile range) for non-normally distributed data. Counts and proportions (of available data) was used for dichotomous data. Statistical analyses were conducted with chi-square tests for categorical variables, and one-way ANOVA or Kruskal-Wallis test for continuous variables. P values less than 0.05 were deemed to be significant. Bonferroni correction was applied where multiple testing occurred. All statistical analyses were performed using R (version 4.0.2, R Core Team, Vienna, Austria)

Results

The flow of study participants is shown in Figure 1. There were 730 patients who were admitted with TBI, SAH and ICH to the neuroscience ICU between January 1st 2015 to July 22nd 2018. Of those patients, 10 did not consent to have their information used for research purposes. Of those remaining, there were 240 patients who had an EVD during admission and 190 with at least one CSF sample collected from the EVD.

The demographics and clinical characteristics of the included population are shown in Table 1. Invasive mechanical ventilation was required in 158 (83.2%) of our patient cohort, with a median (interquartile range (IQR)) duration of ventilation of 6 (IQR 2-13) days. The median (IQR) number of days receiving sedative agents was 3 (2 to 9). The median duration of EVD placement was 12 (IQR 7-17). Additional details regarding the severity of illness specific to the subgroups with ICH, SAH and TBI are shown in Supplemental Table 1.

The clinical cohort included 6 (3.2%) cases where a diagnosis of VRI was confirmed with a positive CSF culture. There were 29 (15.3%) participants who were treated for VRI. The clinical, laboratory and microbiological details of those with a confirmed diagnosis of VRI and those treated for VRI are shown in Table 2.

The estimate of the incidence of ventriculitis in the cohort varied from 0.5% to 95% when the various published sets of diagnostic criteria were used to define cases of VRI in this cohort, as shown in Table 3 and Figure 2.

Discussion

We performed a retrospective cohort study to assess the variation in the incidence of VRI in a large cohort of patients with acute severe brain injury. We found that most patients with acute severe brain injury have a clinical condition or intervention such as a requirement for invasive mechanical ventilation that makes clinical parameters unreliable in the diagnostic assessment for VRI. We found an unacceptable degree of variation in the estimated incidence of VRI according to the published diagnostic criteria. The lack of clarity in defining a case of VRI was associated with a clinical impact, with a significant proportion of patients being treated with broad spectrum antimicrobial medications, in spite of failing to meet published diagnostic criteria for ventriculostomy related infection. A consistent, objective and universal set of diagnostic criteria for ventriculostomy related infection is needed.

In contrast to the previous published systematic review,⁸ our analysis also looked at the clinical impact of the variance in the definition by including patients treated for VRI, rather than simply including samples with a positive CSF culture. The results of our analysis are in accordance with the findings of Lewis et al, confirming wide variation in the estimated incidence of VRI.⁸ The proportion of patients treated for VRI in our cohort was in keeping with the findings of a previous systematic review that reported an incidence of VRI of approximately 23% across 42 studies assessing diagnostics criteria for VRI.¹⁰ In keeping with the results of that review, we excluded clinical factors that were known to be of limited diagnostic value in this critically ill population.¹⁰

There are a number of strengths to this study. We used prospectively collected data on consecutive, consenting participants to avoid selection bias. We used standard, a-priori definitions for cases of culture positive and treated cases of VRI, including only robust data points in these definitions. We included a diverse population of patients with SAH, TBI and ICH, representative of the population at risk for VRI in usual clinical practice. There are also a number of limitations to this analysis. Only small numbers of cases with positive cultures were identified, and as a single centre study, the results of this study may not be generalisable to other settings.

The major implication of this study for researchers and clinicians is that a standard definition of VRI is required. Clinical decisions regarding the use of broad-spectrum antimicrobial agents, the requirement for replacement of the EVD and delays in placement of a permanent

VP shunt all hinge on having an accurate diagnosis of VRI. The variation in the estimated incidence leads to uncertainty for clinicians and patients and increases unnecessary practice variation. A standard definition of VRI is also essential for researchers to design and conduct the well-designed studies of diagnostic accuracy that are required to further knowledge in this area.¹⁰ The implementation of a bundle to prevent EVD infection has been suggested to be a quality indicator for Neurocritical care units.³¹ For this measure to be widely implemented, a standard definition of VRI is required in order for units to be able to compare their performance.

Conclusion

The multiple available definitions of VRI are associated with an unacceptable broad estimated incidence of the incidence of this condition. Clinical conditions and interventions are common in this cohort of patients and limit the utility of including these variables as part of a robust diagnostic criteria. An objective, consistent and universal definition of VRI is needed.

Acknowledgements.

The authors would like to acknowledge the study participants and their families for consenting to participate in this study.

Conflicts of interest

The authors certify that there is no conflict of interests with any financial organization regarding the material discussed in this manuscript.

Funding

This research was conducted without specific funding. The authors would like to acknowledge the support of the Northcare foundation in supporting the NOICE registry.

Authors contributions

Sara N. Bassin, Simon Chadwick, Oliver Flower, Pierre Janin, and Anthony Delaney conceived the study and wrote the initial study protocol, with critical revisions and input from Jonathan Parkinson and Archie Darbar

Sara N. Bassin, Emily Fitzgerald and Sajeev Mahendran collected data. David Tian performed the statistical analysis.

Sara N. Bassin MD and Anthony Delaney wrote the initial draft of the manuscript that was revised for important intellectual content by David Tian, Simon Chadwick, Sajeev Mahendran, Oliver Flower, Johnathan Parkinson, Archie Darbar and Pierre Janin.

All authors have read and approved the final version of the manuscript.

References

1. Srinivasan V, O'Neill B, Jho D, Donald W, Oh M. The history of external ventricular drainage. *Journal of Neurosurgery*. 2014;120(1):228-36.
2. Tavakoli S, Peitz G, Ares W, Hafeez S, Grandhi R. Complications of invasive intracranial pressure monitoring devices in neurocritical care. *Neurosurg Focus*. 2017 Nov;43(5):E6. PubMed PMID: 29088962. Epub 2017/11/02. eng.
3. Beer R, Lackner P, Pfausler B. Nosocomial ventriculitis and meningitis in neurocritical care patients. *Journal of Neurology*. 2008;255(11):1617–24.
4. Dasenbrock HH, Rudy RF, Smith TR, Guttieres D, Frerichs KU, Gormley WB, et al. Hospital-Acquired Infections after Aneurysmal Subarachnoid Hemorrhage: A Nationwide Analysis. *World Neurosurg*. 2016 Apr;88:459-74. PubMed PMID: 26546996. Epub 2015/11/08. eng.
5. Sam JE, Lim CL, Sharda P, Wuhab NA. The Organisms and Factors Affecting Outcomes of External Ventricular Drainage Catheter-Related Ventriculitis: A Penang Experience. *Asian Journal of Neurosurgery*. 2018;13(2):250-7.
6. Hersh EH, Yaeger KA, Neifert SN, Kim J, Dangayach NS, Weiss N. Patterns of Health Care Costs Due to External Ventricular Drain Infections. *World Neurosurg*. 2019 Aug;128:e31-e7. PubMed PMID: 30928594. Epub 2019/04/01. eng.
7. Fried HI, Nathan BR, Rowe AS, Zabramski JM, Andaluz N, Bhimraj A, et al. The Insertion and Management of External Ventricular Drains: An Evidence-Based Consensus Statement : A Statement for Healthcare Professionals from the Neurocritical Care Society. *Neurocrit Care*. 2016 Feb;24(1):61-81. PubMed PMID: 26738503. Epub 2016/01/08. eng.
8. Lewis A, Wahlster S, Karinja S, Czeisler B, Kimberly T, Lord A. Ventriculostomy-related Infections (VRI): the Performance of Different Definitions for Diagnosing Infection. *Br J Neurosurg*. 2016;30(1):49-56.
9. Muttaiyah S, Ritchie S, Upton A, Roberts S. Clinical parameters do not predict infection in patients with external ventricular drains: a retrospective observational study of daily cerebrospinal fluid analysis. *J Med Microbiol*. 2008;57:207-9.
10. Dorresteyn K, Jellema K, van de Beek D, Brouwer MC. Factors and measures predicting external CSF drain-associated ventriculitis: A review and meta-analysis. *Neurology*. 2019 Nov 26;93(22):964-72. PubMed PMID: 31659095. Epub 2019/10/30. eng.
11. Ramanan M, Shorr A, Lipman J. Ventriculitis: Infection or Inflammation. *Antibiotics (Basel)*. 2021 Oct 14;10(10). PubMed PMID: 34680826. Pubmed Central PMCID: PMC8532926. Epub 2021/10/14. eng.

12. Arulkumaran N, Routledge M, Schlebusch S, Lipman J, Conway Morris A. Antimicrobial-associated harm in critical care: a narrative review. *Intensive Care Med.* 2020 Feb;46(2):225-35. PubMed PMID: 31996961. Pubmed Central PMCID: PMC7046486. Epub 20200129. eng.
13. Fitzgerald E, Hammond N, Tian DH, Bradford C, Flower O, Harbor K, et al. Functional outcomes at 12 months for patients with traumatic brain injury, intracerebral haemorrhage and subarachnoid haemorrhage treated in an Australian neurocritical care unit: A prospective cohort study. *Aust Crit Care.* 2020 Jul 29. PubMed PMID: 32739245. Epub 2020/08/03. eng.
14. von Elm E, Altman D, Egger M, Pocock S, Gøtzsche P, Vandenbroucke J. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)statement: guidelines for reporting observational studies. *J Clin Epidemiol.* 2008;61(4):344-9. Pubmed Central PMCID: 18313558.
15. Teasdale G, Drake C, Hunt W, Kassell N, Sano K, Pertuiset B, et al. A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies. *J Neurol Neurosurg Psychiatry.* 1988;51(11):1457.
16. Claassen J, Bernardini G, Kreiter K, Bates J, Du Y, Copeland D, et al. Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: the Fisher scale revisited. *Stroke.* 2001;32(9):2012-20.
17. Maas A, Hukkelhoven C, Marshall L, Steyerberg E. Prediction of outcome in traumatic brain injury with computed tomographic characteristics: a comparison between the computed tomographic classification and combinations of computed tomographic predictors. *Neurosurgery.* 2005;57(6):1173-82.
18. Hemphill J, Bonovich D, Besmertis L, Manley G, Johnston S. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. *Stroke.* 2001;32(4):891-7.
19. Royal College of Pathologists of Australasia Manual.
<https://www.rcpa.edu.au/Manuals/RCPA-Manual2015>; 7th:[Available from:
<https://www.rcpa.edu.au/Manuals/RCPA-Manual>.
20. Arabi Y, Memish ZA, Balkhy HH, Francis C, Ferayan A, Al Shimemeri A, et al. Ventriculostomy-associated infections: incidence and risk factors. *Am J Infect Control.* 2005 Apr;33(3):137-43. PubMed PMID: 15798667. eng.
21. Hopkins SJ, McMahon CJ, Singh N, Galea J, Hoadley M, Scarth S, et al. Cerebrospinal fluid and plasma cytokines after subarachnoid haemorrhage: CSF interleukin-6

- may be an early marker of infection. *J Neuroinflammation*. 2012 Nov 23;9:255. PubMed PMID: 23176037. Pubmed Central PMCID: PMC3526412. Epub 20121123. eng.
22. Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES, Jr. Ventriculostomy-related infections: a critical review of the literature. *Neurosurgery*. 2002 Jul;51(1):170-81; discussion 81-2. PubMed PMID: 12182415. eng.
23. McLaughlin N, St-Antoine P, Bojanowski MW. Impact of antibiotic-impregnated catheters on the timing of cerebrospinal fluid infections in non-traumatic subarachnoid hemorrhage. *Acta Neurochir (Wien)*. 2012 Apr;154(4):761-6; discussion 7. PubMed PMID: 22310970. Epub 20120204. eng.
24. Mikhaylov Y, Wilson TJ, Rajajee V, Thompson BG, Maher CO, Sullivan SE, et al. Efficacy of antibiotic-impregnated external ventricular drains in reducing ventriculostomy-associated infections. *J Clin Neurosci*. 2014 May;21(5):765-8. PubMed PMID: 24411330. Epub 20140108. eng.
25. Rath PM, Schoch B, Adamzik M, Steinmann E, Buer J, Steinmann J. Value of multiplex PCR using cerebrospinal fluid for the diagnosis of ventriculostomy-related meningitis in neurosurgery patients. *Infection*. 2014 Aug;42(4):621-7. PubMed PMID: 24470322. Epub 20140129. eng.
26. Schoch B, Regel JP, Nierhaus A, Wichert M, Mueller OM, Sandalcioğlu IE, et al. Predictive value of intrathecal interleukin-6 for ventriculostomy-related Infection. *Zentralbl Neurochir*. 2008 May;69(2):80-6. PubMed PMID: 18444215. Epub 20080429. eng.
27. Tse T, Cheng K, Wong K, Pang K, Wong C. Ventriculostomy and Infection: A 4-year-review in a local hospital. *Surg Neurol Int*. 2010 Sep 9;1:47. PubMed PMID: 20975968. Pubmed Central PMCID: PMC2958322. Epub 20100909. eng.
28. Wright K, Young P, Brickman C, Sam T, Badjatia N, Pereira M, et al. Rates and determinants of ventriculostomy-related infections during a hospital transition to use of antibiotic-coated external ventricular drains. *Neurosurg Focus*. 2013 May;34(5):E12. PubMed PMID: 23634916. eng.
29. Stenager E, Gerner-Smidt P, Kock-Jensen C. Ventriculostomy-related infections--an epidemiological study. *Acta Neurochir (Wien)*. 1986;83(1-2):20-3. PubMed PMID: 3799246. eng.
30. Zabramski JM, Whiting D, Darouiche RO, Horner TG, Olson J, Robertson C, et al. Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. *J Neurosurg*. 2003 Apr;98(4):725-30. PubMed PMID: 12691395. eng.

31. Livesay S, Fried H, Gagnon D, Karanja N, Lele A, Moheet A, et al. Clinical Performance Measures for Neurocritical Care: A Statement for Healthcare Professionals from the Neurocritical Care Society. *Neurocrit Care*. 2020 Feb;32(1):5-79. PubMed PMID: 31758427. Epub 2019/11/24. eng.
32. Arabi Y, Memish Z, Balkhy H, Francis C, Ferayan A, Al Shimemeri A, et al. Ventriculostomy-associated infections: incidence and risk factors. *Am J Infect Control*. 2005;33:137-43.
33. Bota D, Lefranc F, Vilallobos H, Brimiouille S, Vincent J. Ventriculostomy-related infections in critically ill patients: a 6-year experience *J Neurosurg*. 2005;103:468-72.
34. Chi H, Chang KY, Chang HC, Chiu NC, Huang FY. Infections associated with indwelling ventriculostomy catheters in a teaching hospital. *Int J Infect Dis*. 2010 Mar;14(3):e216-9. PubMed PMID: 19647466. Epub 2009/07/31. eng.
35. Gozal YM, Farley CW, Hanseman DJ, Harwell D, Magner M, Andaluz N, et al. Ventriculostomy-associated infection: a new, standardized reporting definition and institutional experience. *Neurocrit Care*. 2014 Aug;21(1):147-51. PubMed PMID: 24343563. eng.
36. Holloway KL, Barnes T, Choi S, Bullock R, Marshall LF, Eisenberg HM, et al. Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients. *J Neurosurg*. 1996 Sep;85(3):419-24. PubMed PMID: 8751626. eng.
37. Lyke K, Obasanjo O, Williams M, O'Brien M, Chotani R, Perl T. Ventriculitis complicating use of intraventricular catheters in adult neurosurgical patients *Clinical Infectious Diseases*. 2001;33:2028-33.
38. Mayhall C, Archer N, Lamb V. Ventriculostomy-related infections: a prospective epidemiologic study. *N Engl J Med*. 1984;310:553-9.

Table 1.
Characteristics of the cohort

	All patients (n=190)	ICH (n=30)	SAH (n=111)	TBI (n=49)	P value
Median age (IQR)	58 (48-72)	58 (47-75)	60 (52-71)	54 (41-69)	0.006
Female n(%)	106 (55.8)	15 (50.0)	76 (68.5)	15 (30.6)	<0.001
ICH SAH TBI	30 (15.8) 111 (58.4) 49 (25.8)	30	111	49	NA
Median APACHE III (IQR)	53 (32-73)	56 (40-71)	41 (29-68)	65 (53-85)	<0.001
Pre-morbid function					0.037
- Independent in ADLs	180 (94.7)	28 (93.3)	108 (97.3)	44 (89.8)	
- Some assistance with ADLs	7 (3.7)	1 (3.3)	1 (0.9)	5 (10.2)	
- Dependent	2 (1.1)	1 (3.3)	1 (0.9)	0 (0.0)	
Pre-morbid residence					0.701
- Own residence	185 (97.4)	29 (96.7)	108 (97.3)	48 (98.0)	
- Low level care	2 (1.1)	0 (0.0)	1 (0.9)	1 (2.0)	
- Nursing home	3 (1.6)	1 (3.3)	2 (1.8)	0 (0.0)	
Premorbid conditions					NA
- Cardiac failure	0	0	0	0	0.338
- PVD	3 (1.6)	0	3 (2.7)	0	0.658
- Myocardial infarction	4 (2.1)	0	3 (2.7)	1 (2.0)	0.049
- Cerebrovascular disease	9 (4.7)	4 (13.3)	4 (3.6)	1 (2.0)	0.836
- COPD	11 (5.8)	2 (6.7)	7 (6.3)	2 (4.1)	0.444
- Dementia	4 (2.1)	0	2 (1.8)	2 (4.1)	0.939
- Chronic kidney disease	5 (2.6)	1 (3.3)	3 (2.7)	1 (2.0)	
Smoking status					0.015
- Current Smoker	46 (24.2)	6 (20.0)	33 (29.7)	7 (14.3)	
- Ex-smoker	17 (8.9)	4 (13.3)	11 (9.9)	2 (4.1)	
- Never smoked	59 (31.1)	9 (30.0)	38 (34.2)	12 (24.5)	

- Unknown	68 (35.8)	11 (36.7)	29 (26.1)	28 (57.1)	
ICU mortality	32 (16.8)	5 (16.7)	18 (16.2)	9 (18.4)	0.945
Hospital mortality	38 (20.0)	6 (20.0)	22 (19.8)	10 (20.4)	0.996
Mechanically ventilated	158 (83.2)	28 (93.3)	82 (73.9)	48 (98)	<0.001
- Median days mechanically ventilated (IQR)	6 (2-13)	5 (3-13)	4 (2-11)	9 (6-17)	0.006
Median days with EVD (IQR)	12 (7-17)	11 (8-16)	14 (8-19)	8 (5-11)	<0.001
Median ICU LOS (IQR)	17 (10-21)	16 (10-29)	18 (13-21)	12 (8-20)	0.082
Median hospital LOS (IQR)	28 (19-42)	30 (21-46)	26 (20-34)	31 (14-56)	0.081
Ventriculitis confirmed	6 (3.2)	1 (3.3)	3 (2.7)	2 (4.1)	0.898
Ventriculitis suspected	73 (38.4)	6 (20.0)	55 (49.5)	12 (24.5)	0.001
Ventriculitis treated	29 (15.3)	1 (3.3)	23 (20.7)	5 (10.2)	0.033
Maximum WCC during admission (median, IQR)	17.0 (14.0-20.7)	16.5 (13.3-21.3)	16.9 (14.4-20.2)	18.0 (14.2-21.8)	0.613
Average WCC during admission (median, IQR)	11.2 (9.6-12.9)	10.4 (9.2-11.7)	11.3 (9.7-13.1)	11.3 (9.7-12.9)	0.230
Proportion of ICU stay on sedation	30.4 (10.1-60.0)	24.0 (12.9-57.9)	15.4 (5.0-38.8)	61.9 (40.0-78.6)	<0.001
Sedative days (median, IQR)	3 (2-9)	3 (2-11)	2 (1-6)	8 (4-12)	<0.001

ICH = Intracerebral haemorrhage, SAH = subarachnoid haemorrhage, TBI= traumatic brain injury, IQR = interquartile range, APACHE = Acute physiology and chronic health evaluation, ADL = activities of daily living, PVD = peripheral vascular disease, COPD chronic obstructive pulmonary disease, ICU = Intensive care unit, LOS = length of stay, WCC = white cell count

Table 2

Clinical, and laboratory features of clinical cases of VRI confirmed by positive culture, treated cases and suspected cases.

	Culture positive VRI (n=6)	Treated VRI (n=29)	Suspected VRI (n=73)	No suspicion of VRI (n=112)	P value
Age	55 ± 17	55 ± 17	58 ± 14	58 ± 16	0.866
Male	4 (67)	13 (45)	25 (34)	57 (51)	0.106
Primary pathology					0.001
ICH	1 (17)	1 (3)	6 (8)	24 (21)	
SAH	3 (50)	23 (79)	55 (75)	52 (46)	
TBI	2 (33)	5 (17)	12 (16)	36 (32)	
Median APACHE III	56 (40-68)	37 (30-63)	39 (29-63)	61 (42-77)	0.001
Median EVD days	18 (14-23)	16 (13-23)	17 (13-21)	8 (4-13)	<0.001
Ventilation on day of diagnosis n (%)	3 (50)	11 (38)	34 (47)	74 (67)	0.010
ICU LOS	22 (19-33)	20 (15-26)	20 (15-28)	13 (8-19)	<0.001
Hospital LOS	48 (32-60)	30 (25-53)	30 (24-47)	24 (12-35)	<0.001
Temperature (first day of diagnosis)*	38.0 ± 0.8	38.3 ± 0.7	37.8 ± 0.7	37.0 ± 3.6	<0.001
WCC (first day of diagnosis)*	8.0 (6.0-8.8)	11.4 (9.1-15.0)	12.9 (11.6-14.4)	10.3 (8.4-14.1)	<0.001
CRP first day of diagnosis*	59 (38-198)	31 (16-59)	32 (17-90)	12 (5-43)	0.001
CSF sample*					
WCC	330 (127-1424)	141 (54-333)	31 (10-138)	22 (5-55)	<0.001
RBC:WCC ratio	52:1	63:1	60:1	257:1	<0.001
CSF glucose	4.2 ± 0.8	4.0 ± 0.7	4.6 ± 0.6	4.8 ± 1.5	0.079
Protein	0.7 ± 0.4	0.7 ± 0.3	0.6 ± 0.4	1.4 ± 2.2	0.757
Lactate	3.6 ± 1.8	3.5 ± 0.8	2.9 ± 0.9	3.1 ± 1.6	0.216
BSL*	7.7 ± 1.4	7.4 ± 1.1	7.7 ± 1.3	8.2 ± 2.4	0.670
Vasospasm	1 (17)	18 (62)	35 (48)	17 (15)	<0.001


VRI = ventriculostomy related infection, ICH = intracerebral haemorrhage, SAH = subarachnoid haemorrhage, TBI = traumatic brain injury, APACHE = Acute physiology and chronic health evaluation, EVD = external ventricular drain, ICU = intensive care unit, LOS = length of stay, WCC = white cell count, CRP = C reactive protein, CSF = cerebrospinal fluid, RBC = red blood cell, BSL = blood sugar level. * For patients without a diagnosis or suspicion of VRI, the worst CSF sample results based on WCC and RBC:WCC ratio and the day this occurred were included for comparison

Table 3.

The incidence of ventriculitis according to the published definitions

Definition	N Ventriculitis (%)	ICH (n=30)	SAH (n=111)	TBI (n=49)
Arabi ³²	10 (5.3)	1 (3.3)	7 (6.3)	2 (4.1)
Bota ³³	1 (0.5)	1 (3.3)	0 (0.0)	0 (0.0)
Chi ³⁴	7 (3.7)	1 (3.3)	4 (3.6)	2 (4.1)
Gozal ³⁵	1 (0.5)	1 (3.3)	0 (0.0)	0 (0.0)
Holloway ³⁶	95 (50)	9 (30.0)	71 (64.0)	15 (30.6)
Hopkins ²¹	158 (83.2)	27 (90.0)	99 (89.2)	32 (65.3)
Lozier ²²	62 (32.6)	8 (26.7)	41 (36.9)	13 (26.5)
Lyke ³⁷	3 (1.6)	1 (3.3)	2 (1.8)	0 (0.0)
Mayhall ³⁸	7 (3.7)	1 (3.3)	4 (3.6)	2 (4.1)
McLaughlin ²³	82 (43.2)	12 (40.0)	53 (47.7)	17 (34.7)
Mikhaylov ²⁴	7 (3.7)	1 (3.3)	4 (3.6)	2 (4.1)
Rath ²⁵	33 (17.4)	6 (20.0)	22 (19.8)	5 (10.2)
Schoch ²⁶	34 (17.9)	6 (20.0)	23 (20.7)	5 (10.2)
Stenager ²⁹	7 (3.7)	1 (3.3)	4 (3.6)	2 (4.1)
Tse ²⁷	4 (2.1)	1 (3.3)	1 (0.9)	2 (4.1)
Wright ²⁸	178 (93.7)	28 (93.3)	109 (98.2)	41 (83.7)
Zabramski ³⁰	5 (2.6)	1 (3.3)	2 (1.8)	2 (4.1)
Clinical VRI confirmed	6 (3.2)	1 (3.3)	3 (2.7)	2 (4.1)
Clinical VRI suspected	73 (38.4)	6 (20.0)	55 (49.5)	12 (24.5)
Clinical VRI treated	29 (15.3)	1 (3.3)	23 (20.7)	5 (10.2)

Figure 1
Flow of included patients



ICU = intensive care unit, TBI = traumatic brain injury, SAH= subarachnoid haemorrhage, ICH = intracerebral haemorrhage, CSF = cerebrospinal fluid

Figure 2

The incidence of ventriculitis in patients with ICH, TBI and SAH according to available published definitions.

